Lipid nanoparticle (LNP) technology has rapidly emerged as a transformative modality for the delivery of nucleic acids, proteins, and other biologically active molecules. With its unique ability to encapsulate delicate biomolecules and transport them into specific tissues and cells, LNP has become a cornerstone in advancing next-generation therapeutics. Unlike conventional delivery vehicles, LNPs offer superior safety profiles, high encapsulation efficiency, scalable manufacturing, and remarkable versatility in payload selection. Alfa Chemistry has pioneered innovations in LNP design and application, supported by a strong intellectual property portfolio. By harnessing these proprietary technologies, we have established four featured service platforms that address critical challenges in precision medicine and translational science: Extrahepatic Delivery Platform, Gene Editing Platform, Antibody-LNP Conjugates Platform, and In vivo CAR-T Platform. These platforms collectively expand the boundaries of drug delivery and therapeutic possibilities, enabling new approaches in genetic medicine, oncology, immunology, and rare diseases.
Fig. 1. (Left) Targeted LNP and (right) general composition of LNP.
Our Platforms: A Comprehensive Suite of Solutions
Extrahepatic Delivery Platform
Our extrahepatic delivery platform is built upon proprietary LNP technology and our patented library of novel ionizable lipids. By integrating rational lipid design, novel formulation processes, and advanced targeting methodologies, we have achieved efficient delivery of various RNA therapeutics (including mRNA, siRNA, and circRNA, as well as gene editing tools.) to multiple extrahepatic tissues such as spleen, lung, skin, immune cells.
Gene Editing Platform
Our gene editing platform leverages proprietary LNP systems to meet the diverse needs of gene editing therapeutics. It offers cargo flexibility, supporting delivery of mRNA-sgRNA pairs, RNPs (ribonucleoprotein complexes), and base editors. The platform is highly adaptable, serving both in vitro research and in vivo therapeutic development.
Antibody-LNP Conjugates Platform
The platform achieves the dual advantages of "antibody specificity recognition + efficient LNP delivery" by binding antibodies to LNP. The antibodies can accurately guide the LNPs to target cells, while the LNPs efficiently release nucleic acids or small molecule drugs, significantly enhancing the therapeutic targeting and efficacy. Moreover, our conjugation strategies encompass various methods including chemical cross-linking, affinity tagging, and lipid-antibody conjugation techniques, ensuring high stability and low immunogenicity.
In vivo CAR-T Platform
We have developed an in vivo CAR-T platform. This platform is based on mRNA-LNP delivery technology, which enables the direct delivery of CAR genes to T cells in vivo, achieving in situ modification and functional enhancement. It is particularly noteworthy that we have developed the "In Spleen CAR-T" strategy, where LNPs selectively deliver mRNA cargo to T cells within the spleen, the natural hub of immune activation.
Our four featured LNP-based delivery platforms showcase the versatility and transformative potential of LNP technology. Each platform addresses a distinct challenge in modern medicine, whether it is expanding tissue reach, enabling curative genetic interventions, enhancing targeted delivery, or simplifying complex cell therapies.
Together, these platforms form a comprehensive ecosystem that supports academic researchers, biotech innovators, and pharmaceutical developers in advancing the next generation of precision medicines. With a strong foundation in proprietary LNP innovations and a commitment to translational success, we are redefining the landscape of drug delivery and therapeutic discovery. We welcome partners from academia and industry to collaborate with us, leveraging our platforms to accelerate research, development, and commercialization of groundbreaking therapies. By working together, we can bring transformative medicines to patients faster and more effectively.
Our products and services are for research use only and cannot be used for any clinical purposes.
